IP Library › Granted Patent US 11,214,614
Granted Patent B2
US 11,214,614 · App. 16/997,438 · Granted Jan 4, 2022

LTBP complex-specific inhibitors of TGFβ and uses thereof

Inventors: Thomas Schurpf (Cambridge, MA); Justin W. Jackson (Cambridge, MA); George Coricor (Cambridge, MA); Abhishek Datta (Boston, MA); Stefan Wawersik (Westborough, MA); Christopher Littlefield (Marblehead, MA); Adam Fogel (Watertown, MA); Caitlin Stein (Lebanon, NH); Julia McCreary (Lebanon, NH); Matthew Salotto (Lebanon, NH); Frederick Streich, Jr. (Newton, MA)
Assignee: Scholar Rock, Inc.
C07K16/22A61P1/16A61P13/12C07K16/2863A61K2039/505C07K2317/32C07K2317/56C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,214,614
App. No.
16/997,438
Granted
Jan 4, 2022
Kind
B2
Abstract

Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.

Claims (3)

1. An antibody, or an antigen-binding fragment thereof, that specifically binds a human LTBP1-proTGFβ complex and a human LTBP3-proTGFβ complex, comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 318 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 319.

2. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO: 318 and the light chain variable domain consists of the amino acid sequence of SEQ ID NO: 319.

3. A pharmaceutical composition comprising the antibody, or the antigen-binding fragment thereof, of claim 1 or claim 2 .

Assignments (9)
SECURITY INTEREST Recorded Mar 3, 2026
From: SCHOLAR ROCK, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075015/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: SCHURPF, THOMAS; JACKSON, JUSTIN W.; DATTA, ABHISHEK; WAWERSIK, STEFAN; LITTLEFIELD, CHRISTOPHER
To: SCHOLAR ROCK, INC.
Reel/Frame 057806/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: CORICOR, GEORGE; FOGEL, ADAM
To: SCHOLAR ROCK, INC.
Reel/Frame 057806/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: SCHOLAR ROCK, INC.
To: ADIMAB, LLC
Reel/Frame 057806/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: STREICH, FREDERICK, JR.
To: SCHOLAR ROCK, INC.
Reel/Frame 057806/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: STEIN, CAITLIN
To: ADIMAB, LLC
Reel/Frame 057806/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: SALOTTO, MATTHEW
To: ADIMAB, LLC
Reel/Frame 057806/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: ADIMAB, LLC
To: SCHOLAR ROCK, INC.
Reel/Frame 057808/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: MCCREARY, JULIA
To: ADIMAB, LLC
Reel/Frame 057806/0736 →
Continuity (3)
Continuation PCTUS2020015915 · Jan 30, 2020
Provisional Application 62798927 · Jan 30, 2019
Related Publication 20210047396A1 · Feb 18, 2021